EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo

Alexa Pichet Binette iD, Angela Mammana, Laura Wisse, Marcello Rossi, Olof Strandberg, Ruben Smith, Niklas Mattsson-Carlgren, Shorena Janelidze, Sebastian Palmqvist, ADNI, Alice Ticca, Erik Stomrud und 2 weitere

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.14225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Alexa Pichet Binette und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: alpha-Synuclein, Alzheimer Disease, Biomarkers, Amyloid beta-Peptides. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regionalt Forskningsstöd, Alzheimer's Disease Neuroimaging Initiative, Eli Lilly and Company; EuroImmun.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We examined the relations of misfolded alpha synuclein (α‐synuclein) with Alzheimer's disease (AD) biomarkers in two large independent cohorts. METHODS We included Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably Two (BioFINDER‐2) and Alzheimer's Disease Neuroimaging Initiative (ADNI) participants ( n = 2315, cognitively unimpaired, mild cognitive impairment, AD dementia) who had cross‐sectional cerebrospinal fluid (CSF) α‐synuclein measurement from seed‐amplification assay as well as cross‐sectional and longitudinal amyloid beta (Aβ) and tau levels (measured in CSF and/or by positron emission tomography). All analyses were adjusted for age, sex, and cognitive status. RESULTS Across cohorts, the main biomarker associated with α‐synuclein positivity at baseline was higher levels of Aβ pathology (all p values ≤ 0.02), but not tau. Looking at longitudinal measures of AD biomarkers, α‐synuclein –positive participants had a statistically significant faster increase of Aβ load, although of modest magnitude (1.11 Centiloid/year, p = 0.02), compared to α‐synuclein –negative participants in BioFINDER‐2 but not in ADNI. DISCUSSION We showed associations between concurrent misfolded α‐synuclein and Aβ levels, providing in vivo evidence of links between these two molecular disease pathways in humans. Highlights: Amyloid beta (Aβ), but not tau, was associated with alpha‐synuclein (α‐synuclein) positivity. Such association was consistent across two cohorts, beyond the effect of age, sex, and cognitive status. α‐synuclein–positive participants had a small, statistically significant faster increase in Aβ positron emission tomography levels in one of the two cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinAlzheimer DiseaseBiomarkersAmyloid beta-Peptidestau ProteinsPositron-Emission TomographyCognitive DysfunctionHumansMaleFemaleAgedCross-Sectional StudiesAged, 80 and overCohort StudiesLongitudinal StudiesMiddle AgedBrain

Stichwörter der Autor:innen

Lewy bodyamyloid betaco‐pathologyneurodegenerative diseasesseed‐amplification assaytau

Substanzen

alpha-SynucleinBiomarkersAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
  • IRCCS, Istituto delle Scienze Neurologiche di Bologna (ISNB), Bologna, Italy.
  • Diagnostic Radiology Unit, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Memory Clinic, Skåne University Hospital, Malmö, Sweden.
  • Department of Neurology, Skåne University Hospital, Malmö, Sweden.
  • Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.

ORCID-Profile: Alexa Pichet Binette

Förderung

  • Regionalt Forskningsstöd
  • Alzheimer's Disease Neuroimaging Initiative
  • Eli Lilly and Company; EuroImmun
  • Piramal Imaging
  • Alzheimer's Association
  • Janssen Alzheimer Immunotherapy Research & Development
  • Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation
  • GHR Foundation, Swedish Research Council

Zitieren

APA

Pichet Binette, A., Mammana, A., Wisse, L., Rossi, M., Strandberg, O., Smith, R., Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., ADNI, Ticca, A., Stomrud, E., Parchi, P., & Hansson, O. (2024). Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14225

Vancouver

Pichet Binette A, Mammana A, Wisse L, Rossi M, Strandberg O, Smith R, et al. Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14225

BibTeX
@article{PichetBinette2024,
  author = {Pichet Binette, Alexa and Mammana, Angela and Wisse, Laura and Rossi, Marcello and Strandberg, Olof and Smith, Ruben and Mattsson-Carlgren, Niklas and Janelidze, Shorena and Palmqvist, Sebastian and ADNI, ADNI and Ticca, Alice and Stomrud, Erik and Parchi, Piero and Hansson, Oskar},
  title = {Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.14225}
}
Kostenlos starten →